United Therapeutics (UTHR) Total Non-Current Liabilities (2009 - 2026)

United Therapeutics has reported Total Non-Current Liabilities for 18 years, with the latest figure at $599.1 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 16.96% year-over-year to $599.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $599.1 million (down 16.96% YoY) and the FY2025 annual result came in at $560.6 million, down 24.05% from the prior year.
• Total Non-Current Liabilities advanced to $599.1 million in Q1 2026 per UTHR's latest filing, from $560.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $1.2 billion in Q3 2023 and troughed at $527.1 million in Q2 2025.
• A 5-year average of $922.7 million and a median of $1.1 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities grew 11.49% in 2023, then slumped 43.46% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $1.1 billion in 2022, then slipped by 3.39% to $1.1 billion in 2023, then slumped by 33.17% to $738.1 million in 2024, then declined by 24.05% to $560.6 million in 2025, then grew by 6.87% to $599.1 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $599.1 million, $560.6 million, and $546.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.